Secondary Outcomes
gynecologic cancer, Cancer
GYNECOLOGIC CANCER, CANCER
At 12 weeks (T1), there was no significant difference in the QoL between the 2 groups. At 24 weeks (T2), after adjusting for the baseline scores, participants who received the MGCS program plus routine care exhibited a significant improvement in QoL compared with participants who only received routine care (Mean change in the measurement outcomes at baseline (T0), 12 weeks (T1), and 24 weeks (T2) (N=168). FACT-G: Functional Assessment of Cancer Therapy-General; MDASI: MD Anderson Symptom Inventory; MGCS: mobile app for gynecologic cancer support; MSPSS: Multidimensional Scale of Perceived Social Support; MUIS-A: Mishel Uncertainty in Illness Scale for Adults.